Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler S, Ramírez-Suástegui C, Li Y, King E, Chudley L, Thomas J, Wood O, von Witzleben A, Jeffrey D, McCann K, Simon H, Mondal M, Wang A, Dicker M, Lopez-Guadamillas E, Chou TF, Dobbs NA, Essame L, Acton G, Kelly F, Halbert G, Sacco JJ, Schache AG, Shaw R, McCaul JA, Paterson C, Davies JH, Brennan PA, Singh RP, Loadman PM, Wilson W, Hackshaw A, Seumois G, Okkenhaug K, Thomas GJ, Jones TM, Ay F, Friberg G, Kronenberg M, Vanhaesebroeck B, Vijayanand P, Ottensmeier CH.
Eschweiler S, et al.
Nature. 2022 May;605(7911):741-746. doi: 10.1038/s41586-022-04685-2. Epub 2022 May 4.
Nature. 2022.
PMID: 35508656
Free PMC article.
Clinical Trial.
Single-cell RNA-sequencing analysis revealed a PI3Kdeltai-driven loss of tissue-resident colonic ST2 T(reg) cells, accompanied by expansion of pathogenic T helper 17 (T(H)17) and type 17 CD8(+) T (T(C)17) cells, which probably contributed to toxicity; this points towards a …
Single-cell RNA-sequencing analysis revealed a PI3Kdeltai-driven loss of tissue-resident colonic ST2 T(reg) cells, accompanied by exp …